ClinicalTrials.gg
CompletedNCT07333742Updated Jan 12, 2026

A Clinical Study to See How the Body Handles and How Safe a Combination Tablet of Gemigliptin, Dapagliflozin, and Metformin 50/10/1000mg is Compared to Taking Gemigliptin 50mg Separately With Dapagliflozin/Metformin 10/1000mg in Healthy Adults After a Meal

A Phase 1 interventional study of Test drug: Fixed-dose combination (FDC) of gemigliptin/dapagliflozin/metformin 50/10/1000 mg and Reference drug: gemigliptin (Zemiglo) 50mg, Xigduo XR 10/1000 mg in Fed Conditions and Healthy Volunteer, sponsored by LG Chem. Completed at 1 site in South Korea. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by LG Chem · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
All
01

Study summary

Bioequivalence study for the fixed-dose combination of gemigliptin/dapagliflozin/metformin 50/10/1000 mg under fed conditions in healthy volunteers

02

Conditions studied

  • Fed Conditions
  • Healthy Volunteer

Keywords

  • Bioequivalence study
  • Fed condition
03

In context

Lead sponsor

LG Chem is the lead sponsor of 71 studies on the registry; 8 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 1 (8%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 19-50 years in healthy volunteers
  2. 18.0 kg/m\^2 ≤ ≤ 29.9 kg/m\^2, 50kg ≤weight ≤ 90kg
  3. 60≤ FPG≤125 mg/dL
  4. Subjects who voluntarily decides to participate in this clinical trial and agree in writing to ensure compliance with the clinical trial.

Exclusion criteria

Exclusion Criteria:

  1. Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including disorders in digestive system, neuropsychiatric system, endocrine system, liver, cardiovascular system.
  2. Subjects with clinically significant abnormal findings during tests (or examinations)
  3. Subjects with a history of or clinically significant hypersensitivity reactions to test drugs or other drugs
  4. Subjects judged ineligible by the investigator
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Sequence A

    Sequence A: Test drug -\> Reference drug

    Drug: Test drug: Fixed-dose combination (FDC) of gemigliptin/dapagliflozin/metformin 50/10/1000 mg · Drug: Reference drug: gemigliptin (Zemiglo) 50mg, Xigduo XR 10/1000 mg

  • Experimental
    Sequence B

    Sequence B: Reference drug -\> Test drug

    Drug: Test drug: Fixed-dose combination (FDC) of gemigliptin/dapagliflozin/metformin 50/10/1000 mg · Drug: Reference drug: gemigliptin (Zemiglo) 50mg, Xigduo XR 10/1000 mg

Interventions

  • DrugTest drug: Fixed-dose combination (FDC) of gemigliptin/dapagliflozin/metformin 50/10/1000 mg

    All participants take 1 tablet of either test drug or reference drug after meal.

  • DrugReference drug: gemigliptin (Zemiglo) 50mg, Xigduo XR 10/1000 mg

    Drug page: Gemigliptin

    All participants take 1 tablet of either test drug or reference drug after meal.

06

What researchers measure

Primary outcomes

  1. The plasma concentration of gemigliptin, dapagliflozin, and metformin

    Primary Parameters: Area under the plasma concentration versus time curve (AUClast) of gemigliptin, dapagliflozin, and metformin

    Time frame: - Period 1: 16 times up to 72 hours from IP administration - Period 2: 16 times up to 72 hours from IP administration

  2. The plasma concentration of gemigliptin, dapagliflozin, and metformin

    Primary Paramenters: Peak Plasma Concentration (Cmax) of gemigliptin, dapagliflozin, and metformin

    Time frame: - Period 1: 16 times up to 72 hours from IP administration - Period 2: 16 times up to 72 hours from IP administration

Secondary outcomes

  1. The plasma concentration of gemigliptin, dapagliflozin and metformin

    Secondary Parameters: Time to Maximum(Tmax) Concentration of gemigliptin, dapagliflozin, and metformin

    Time frame: Period 1: 16 times up to 72 hours from IP administration Period 2: 16 times up to 72 hours from IP administration

  2. The plasma concentration of gemigliptin, dapagliflozin and metformin

    Secondary Parameters: Lag Time(Tlag) of gemigliptin, dapagliflozin, and metformin

    Time frame: - Period 1: 16 times up to 72 hours from IP administration - Period 2: 16 times up to 72 hours from IP administration

  3. The plasma concentration of gemigliptin, dapagliflozin and metformin

    Secondary Parameters: Area Under the Curve to Infinity(AUCinf) of gemigliptin, dapagliflozin, and metformin

    Time frame: - Period 1: 16 times up to 72 hours from IP administration - Period 2: 16 times up to 72 hours from IP administration

  4. The plasma concentration of gemigliptin, dapagliflozin and metformin

    Secondary Parameters: Half-life(t1/2) of gemigliptin, dapagliflozin, and metformin

    Time frame: - Period 1: 16 times up to 72 hours from IP administration - Period 2: 16 times up to 72 hours from IP administration

  5. The plasma concentration of gemigliptin, dapagliflozin and metformin

    Secondary Parameters: Apparent Clearance(CL/F) of gemigliptin, dapagliflozin, and metformin

    Time frame: - Period 1: 16 times up to 72 hours from IP administration - Period 2: 16 times up to 72 hours from IP administration

  6. The plasma concentration of gemigliptin, dapagliflozin and metformin

    Secondary Parameters: Apparent Volume of Distribution(Vz/F) of gemigliptin, dapagliflozin, and metformin

    Time frame: - Period 1: 16 times up to 72 hours from IP administration - Period 2: 16 times up to 72 hours from IP administration

Other outcomes

  1. Assessment - Safety (Adverse events)

    A list of all adverse events for each treatment group and for all participants with seriousness, severity, relationship with investigational product. A number of participant with adverse event.

    Time frame: up to day 18 (post study visit)

  2. Assessment - Safety (Physical examination)

    Any finding in general condition, nutritional status and other category by medical interview

    Time frame: 3 times until 72 hours from IP administration

  3. Assessment - Safety (Vital sign)

    Systolic Blood Pressure(mmHg), Diastolic Blood Pressure(mmHg), Pulse Rate(beats/min), Temperature(℃)

    Time frame: 7 times until 72 hours from IP administration

  4. Assessment - Safety (12-lead ECG results)

    Ventricular rate(beats/min), PR interval(msec), QRS(msec), QT(msec), QTcB(msec)

    Time frame: 4 times until post-study visit

  5. Assessment - Safety (Clinical laboratory test results)

    Hematology, Blood Chemistry, Urinalysis

    Time frame: 4 times until post-study visit

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, 03080, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2025 to primary completion in Nov 2025, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Jan 12, 2026
StartActual
Sep 29, 2025
Primary completionActual
Nov 27, 2025
CompletionActual
Nov 27, 2025
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07333742
Lead sponsor
LG Chem
Responsible party
Sponsor
First posted
Jan 12, 2026
Start date
Sep 29, 2025
Primary completion
Nov 27, 2025
Completion
Nov 27, 2025
Last update
Jan 12, 2026

Study contacts

Kyung-Sang Yu, M.D., Professor
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion